公司資料
MediWound 股價、新聞與催化劑
- 股票代碼:
- MDWD
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Israel
股票表現
13.39 USD (-1.25%)
收盤價
最後更新: 2026年8月17日
177M USD
市值
股價為何變動
As of Aug 17, 2026, MDWD closed down 1.25% at $13.39. No new same-company headline was identified in the current news window.
公司概覽
Enzymatic Tissue Repair Company
MediWound develops non-surgical enzymatic therapies for tissue repair. Its approved product NexoBrid is used for enzymatic removal of burn eschar and is commercialized in the United States, European Union, Japan, and other international markets.
NexoBrid Commercial Foundation
NexoBrid is an approved enzymatic debridement product with established use in specialized burn care. Regional commercialization through partners gives MediWound product revenue and market access while the company continues investing in broader supply capacity.
Emergency Preparedness Role
NexoBrid also has strategic applications in national preparedness and military medicine. A BARDA-supported contract with Vericel covers procurement, inventory management, potential blast-trauma development, and next-generation manufacturing capacity.
EscharEx Chronic Wound Pipeline
EscharEx is a late-stage enzymatic debridement candidate for chronic wounds, including venous leg ulcers, diabetic foot ulcers, and pressure ulcers. MediWound is positioning it as a potential next-generation standard for chronic wound debridement.
Manufacturing and Supply Expansion
MediWound is expanding NexoBrid production capacity to support commercial demand and strategic stockpiling. Regulatory qualification of the enlarged facility is important to the company’s ability to supply additional markets and government preparedness programs.
未來催化劑
- Initiation of an investigator-sponsored EscharEx study in pressure ulcers in the fourth quarter of 2026.
- Interim sample-size assessment and completion of enrollment in the Phase 3 VALUE study by the end of the first quarter of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。